These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapeutic uses of anti-interleukin-6 receptor antibody. Kang S; Tanaka T; Kishimoto T Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313 [TBL] [Abstract][Full Text] [Related]
4. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Paul-Pletzer K Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666 [TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Tanaka T; Kishimoto T Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551 [TBL] [Abstract][Full Text] [Related]
6. The biology and medical implications of interleukin-6. Tanaka T; Kishimoto T Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of the interleukin-6 receptor. Tanaka T; Narazaki M; Kishimoto T Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626 [TBL] [Abstract][Full Text] [Related]
8. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Nishimoto N Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906 [TBL] [Abstract][Full Text] [Related]
9. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Tanaka T; Narazaki M; Ogata A; Kishimoto T Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of IL-6 for the treatment of inflammatory diseases. Nishimoto N; Kishimoto T Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133 [TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. Tanaka T; Narazaki M; Kishimoto T FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125 [TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL-6) Immunotherapy. Tanaka T; Narazaki M; Kishimoto T Cold Spring Harb Perspect Biol; 2018 Aug; 10(8):. PubMed ID: 28778870 [TBL] [Abstract][Full Text] [Related]
15. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Narazaki M; Tanaka T; Kishimoto T Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214 [TBL] [Abstract][Full Text] [Related]
16. Interleukin 6: from bench to bedside. Nishimoto N; Kishimoto T Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601 [TBL] [Abstract][Full Text] [Related]
17. IL-6 in inflammation, immunity, and disease. Tanaka T; Narazaki M; Kishimoto T Cold Spring Harb Perspect Biol; 2014 Sep; 6(10):a016295. PubMed ID: 25190079 [TBL] [Abstract][Full Text] [Related]
18. [Anti-IL-6 : new therapeutic trends]. Candil M; Zufferey P Rev Med Suisse; 2017 Jan; 13(544-545):105-109. PubMed ID: 28703549 [TBL] [Abstract][Full Text] [Related]
19. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269 [TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Ding C; Jones G Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]